Beckman Coulter Diagnostics and Seegene Supply Agreement
News Nov 17, 2014
Beckman Coulter Diagnostics and Seegene Inc. have announced a Molecular Diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter’s new sample-to-answer Molecular Diagnostics instrument, the VERIS MDx System*.
Richard Creager, senior vice president of the MDx Business Unit and chief scientific officer at Beckman Coulter said, “We’re very excited to partner with Seegene and incorporate their novel and proprietary DPO, TOCE and MuDT technologies into our MDx solution. We expect to be able to quickly add to the menu we offer on VERIS with the Seegene Multiplex reagents that enable simultaneous and multiple detection and identification of various types of pathogens in a single test.”
Seegene founder and CEO, Dr. Jong-Yoon Chun, said, “Our observation is that the VERIS system breaks new ground in enabling laboratories to perform MDx testing in the most efficient way possible. This partnership fully supports our promise to contribute to humanity by developing faster, more accurate and cost-effective innovative MDx systems.”
*The VERIS system and VERIS human Cytomegalovirus (CMV) assay are CE cleared in Europe. The system is still in development for the United States; it is not available for in vitro diagnostic use in the United States.
Molecules in Spit Could Help Diagnose ConcussionsNews
Diagnosing a concussion can sometimes be a guessing game, but clues taken from small molecules in saliva may be able to help diagnose and predict the duration of concussions in children, according to Penn State College of Medicine researchers.READ MORE
Breakthrough Discovery In Diagnostic Tools That Can Replace AntibodiesNews
Experts from the University of Leicester have announced the development of polymeric materials with molecular recognition capabilities which hold the potential to outperform natural antibodies in various diagnostic applications.READ MORE
Cell-weighing Method Could Help Doctors Choose Cancer DrugsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE